Krystal Biotech (KRYS) Expected to Announce Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) is expected to be releasing its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect Krystal Biotech to post earnings of $1.70 per share and revenue of $121.8320 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 3, 2026 at 8:30 AM ET.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. The firm had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, analysts expect Krystal Biotech to post $7 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $335.19 on Monday. The firm has a market cap of $9.88 billion, a price-to-earnings ratio of 44.81 and a beta of 0.50. Krystal Biotech has a 1 year low of $130.50 and a 1 year high of $382.54. The firm’s 50 day moving average price is $333.77 and its two-hundred day moving average price is $292.86.

Insider Buying and Selling

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares of the company’s stock, valued at $347,270. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 26,642 shares of company stock valued at $8,243,923. Insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Greenline Wealth Management LLC acquired a new position in Krystal Biotech in the 4th quarter worth about $34,000. Danske Bank A S acquired a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $35,000. UMB Bank n.a. lifted its holdings in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after buying an additional 37 shares during the last quarter. Global Retirement Partners LLC lifted its holdings in shares of Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after buying an additional 142 shares during the last quarter. Finally, Osaic Holdings Inc. grew its stake in shares of Krystal Biotech by 41.4% in the 2nd quarter. Osaic Holdings Inc. now owns 393 shares of the company’s stock valued at $54,000 after buying an additional 115 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

KRYS has been the subject of several research reports. HC Wainwright raised their price objective on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research note on Tuesday, June 16th. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Bank of America boosted their target price on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. TD Cowen upped their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Finally, Evercore reiterated an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 5th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Krystal Biotech has an average rating of “Moderate Buy” and an average target price of $360.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.